SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
preprint
OA: closed
⤵ 2 in-corpus citations
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (2)
- BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response 2020
- BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response 2020
Cited by (2)
- BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response 2020
- BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response 2020
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00